Author: admin

HIV and Infant Feeding Session 2:

Now What? Care, Monitoring, and Treatment Options for Breast/Chestfeeding Parents Living with HIV and Their Infants

Date and Time

April 18th, 2023

10am – 11:30am PT / 1pm – 2:30pm ET

Learning Objectives

• List options for antiretroviral prophylaxis for breast/chestfed infants and appropriate scenarios in which to utilize them.
• Understand common postpartum challenges for breast/chestfeeding parents with HIV and their babies and demonstrate how your clinical practice can support solutions.
• Describe important aspects of team-based care for breast/chestfeeding parents with HIV and their babies.

Register Here

Presented by the Pacific AETC and NCCC

Tilting the Scale: Current Provider Perspectives and Practices on Breastfeeding with HIV in the United States

A new paper worked on by Pacific AETC’s own Co-Principal Investigator,  Monica Hahn, MPH, MS, MD, on breast/chestfeeding for birthing people living with HIV is now available! Published on February 13th, 2023.

Access the paper now

Abstract

Register Now for Medi-Cal Managed Care Changes: What Advocates Need to Know

Date and Time

Jan 26, 2023 10:00 AM

Description

This webinar will discuss changes to Medi-Cal managed care delivery this year, and those coming next year and beyond. It will inform advocates of what to expect in their counties, and how to assist people who newly enroll in managed care or who must change plans.

NHeLP is a State Bar of California-approved MCLE provider. This event has been approved for 1 hour of California MCLE credit. (Attorneys licensed in other states, please check with your state bar.)

This webinar will be recorded. The recording and slides will be sent to all registrants approximately 48 hours after the conclusion of the webinar. The slides will also be sent to all registrants 24 hours prior to the webinar.

Register Here

Please contact the Operations Team (webinars@healthlaw.org) if you have any accommodation requests for the webinar.

STI Expert Hour Webinar

Medication Conundrums in STI Management

Thursday, February 16, 2023

12:00PM – 1:15PM (PST)

Register Today!

1.25 CME units at no cost (details below)

Learning Objectives

• Describe basic principles of antibiotic pharmacokinetics and pharmacodynamics and their relevance to drug dosing and administration
• Develop a plan for common STI medication issues including dosing/administration, side effect management, and allergy management
• Identify drug information resources related to STI/HIV management, reproductive health, breastfeeding, and drug-drug interactions

Meet Our Expert: Katherine Yang, PharmD, MPH

Dr. Yang is a Health Sciences Clinical Professor in the Department of Clinical Pharmacy and the Co-Vice Dean of Clinical Innovation and Entrepreneurship at the University of California, San Francisco School of Pharmacy. She is also an Infectious Diseases Clinical Pharmacist in the UCSF Medical Center. Dr. Yang specializes in pharmacokinetic and pharmacodynamic optimization of the treatment of multi-drug resistant infections, particularly gram-negative bacteria such as Pseudomonas aeruginosa. For the past 3 years, Dr. Yang has focused her efforts on the clinical management of COVID-19.

CME Information

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nevada, Reno School of Medicine and the California Prevention Training Center. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education to physicians. The University of Nevada, Reno School of Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may receive continuing nursing education credit for this educational activity as the ANCC accepts AMA PRA Category 1 Credits through its reciprocity agreement. The University of Nevada, Reno School of Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s).

To request an accommodation for this event, please contact Catalina Macdonald at catalina.macdonald@ucsf.edu at least a week in advance of the event.

Event Contact

Elizabeth Olson, MPH

Clinical Program Manager

elizabeth.olson@ucsf.edu

Visit the CAPTC Website

SPNS Supporting Replication (SURE) of Housing Interventions Request For Proposal (RFP)

A Request for Proposal (RFP) is now available to Ryan White HIV/AIDS Program (RWHAP) service providers for a Special Project of National Significance (SPNS) program titled Supporting Replication (SURE) of Housing Interventions. It includes funding for up to 10 implementation sites that will implement and adapt housing-related intervention strategies for three priority populations of people with HIV experiencing unstable housing.

The purpose of the SURE Housing initiative is to implement and adapt housing-related intervention strategies for three priority populations of people with HIV experiencing unstable housing, who often have the highest HIV-related disparities:

1) people who identify as lesbian, gay, bisexual, transgender, and queer or questioning (LGBTQ+);
2) youth and young adults (aged 18-24); and
3) people who have been justice-involved (defined as any person who is engaged at any point along the continuum of the criminal justice system as a defendant including arrest, incarceration, and community supervision).

The goal of this initiative is to promote the replication of effective housing interventions in the RWHAP to decrease health and housing disparities and improve health outcomes along the HIV care continuum.  This initiative will engage and retain people with HIV experiencing unstable housing in HIV medical care and support services by addressing their housing and behavioral health needs, as needed.

Serving as the Implementation and Technical Assistance Provider, the Corporation for Supportive Housing (CSH), in partnership with Collaborative Solutions, Inc (CSI), will select, issue, and monitor sub-awards of up to $250,000 per funding year for up to ten implementation sites. Sites will be funded from May 1, 2023 – July 31, 2026. CSH and CSI will provide the sites with technical assistance (TA) for implementing and adapting these interventions.

The implementation sites will also participate in a multi-site evaluation to assess the effectiveness of the interventions’ implementation and adaptation. The implementation of housing-related interventions at each site will be evaluated by the Evaluation Provider comprised of Boston University, the University of Massachusetts, Lowell, and JSI Research & Training Institute, Inc.

Additional information can be found in the Request for Proposals.

Application Details

Current RWHAP service providers are eligible to apply. Applications are due no later than 11:59pm ET on February 15, 2023. To learn more about this opportunity, register here for a live webinar taking place on January 10, 2023 at 3PM Eastern.

For more information, contact HRSA.TA@CSH.ORG.

Announcement: ViiV Healthcare HIV Medications to be Discontinued as of January 1, 2024

Last year, ViiV Healthcare (“ViiV”) released a letter notifying health care providers

that the following products will be discontinued in the United States, and will no longer be distributed by ViiV as of January 1, 2024:

• Lexiva (fosamprenavir) 700 mg Tablets and 50 mg/ml Oral Suspension
• Trizivir (abacavir/lamivudine/zidovudine) 300 mg/150 mg/300 mg Tablets
• Selzentry (maraviroc) 25 mg Tablets and 75 mg Tablets
• Tivicay (dolutegravir) 10 mg Tablets and 25 mg Tablets
• Ziagen (abacavir) 300 mg Tablets
• Combivir (lamivudine/zidovudine) 150 mg/300 mg Tablets
• Epzicom (abacavir/lamivudine) 600 mg/300 mg Tablets

In addition, in the letter ViiV stated it would no longer accept new Patient Assistance Program (PAP) applications for the products listed above after 07/01/22.

For any questions or concerns, please contact the ViiV Healthcare Customer Response Center at 1-877-844-8872.